Daniel Perkins
Dr Daniel Perkins, Unit Head of Psychedelics Research and Therapeutics
Data updated
Research Footprint
Daniel Perkins appears in 14 tracked papers (2020–2025), most studied alongside Ayahuasca, LSD and Psilocybin, across Depressive Disorders, Substance Use Disorders (SUD) and Anxiety Disorders.
Most-cited paper: Default Mode Network Modulation by Psychedelics: A Systematic Review (219 citations).
Frequent co-authors: Joseph Sarris, Nathalia Galvão-Coelho and Luiz Tófoli.
Publication Landscape
How the 14 papers Blossom tracks for Daniel Perkins line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Daniel Perkins's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 14 of 14 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Daniel Perkins publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Daniel Perkins publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Daniel Perkins is a clinical researcher active in contemporary psychedelic science with a primary focus on ayahuasca and related tryptamine/harmala alkaloid formulations. The available publication record attributes several large international, cross-sectional surveys to Perkins that investigate adverse effects, the role of context and setting, and associations between ayahuasca consumption and current alcohol and other drug use. This body of work emphasises epidemiological and naturalistic approaches to understanding mental health and wellbeing outcomes among ayahuasca drinkers.
In addition to survey-based research, Perkins is associated with studies that probe mechanistic and translational aspects of psychedelic therapy, including work linking changes in inflammatory biomarkers to the purported antidepressant effects of ayahuasca, and an exploratory clinical study of oral Acacia-based DMT and harmala alkaloid formulations in healthy volunteers. Collectively, these contributions address safety, contextual moderators of outcome, and preliminary biological substrates relevant to therapeutic mechanisms. Affiliations and a full given name were not provided in the available dataset.
Key Impact
Notable for contributions to large-scale international ayahuasca surveys and exploratory human studies of DMT/harmala alkaloid formulations that examine safety, contextual determinants, and biological correlates of psychedelic use.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Daniel Perkins's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Daniel Perkins is associated with.